INMBライブシグナル | Getagraph.comで利益を最大化

買う 107751 min ago

@ $14.06

発行日: 15 2月 2024 @ 05:50

リターン: -14.16%

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:40):

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease...

Stats
本日の出来高	112 020
平均出来高	102 404
時価総額	225.69M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.540 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.23
ATR14	$0.0410 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Moss David J	Buy	18 028	Common Stock
2024-04-19	Moss David J	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Lowdell Mark William	Buy	14 423	Common Stock

INSIDER POWER
97.72
Last 100 transactions
Buy: 3 367 309 \| Sell: 701 956

ボリューム相関

長: 0.16 (neutral)

短: -0.64 (weak negative)

Signal:(70.157) Neutral

INmune Bio Inc 相関

10 最も正の相関
ECPG	0.878
FIVN	0.859
TREE	0.855
IPDN	0.844
PIRS	0.843
CWBR	0.833
LCFY	0.83
STX	0.828
NXST	0.828
PALT	0.826

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

INmune Bio Inc 相関 - 通貨/商品

-0.33
( neutral )

-0.42
( neutral )

0.00
( neutral )

0.46
( neutral )

0.41
( neutral )

0.61
( weak )

INmune Bio Inc 財務諸表

Annual	2023
収益:	$155 000
総利益:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2023
収益:	$155 000
総利益:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2022
収益:	$374 000
総利益:	$374 000 (100.00 %)
EPS:	$-1.600

FY	2021
収益:	$-181 000
総利益:	$0.00 (0.00 %)
EPS:	$-1.751

Financial Reports:

No articles found.

INmune Bio Inc

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

リアルタイムの更新： INmune Bio Inc [INMB]

Upcoming Earnings Alert